Dynavax Technologies reported $1.01B in Assets for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Abbvie ABBV:US $ 143211M 3318M
Adma Biologics ADMA:US $ 308.03M 31.78M
Agenus AGEN:US $ 441.3M 24.65M
Amgen AMGN:US $ 59196M 1969M
AstraZeneca AZN:LN 100273M 5090M
Astrazeneca AZN:US $ 100273M 5090M
Biogen BIIB:US $ 23614.4M 262.9M
Biomarin Pharmaceutical BMRN:US $ 6062.71M 59.38M
Bristol Myers Squibb BMY:US $ 103034M 6280M
Chimerix CMRX:US $ 65.52M 35.02M
Dynavax Technologies DVAX:US $ 1008.98M 30.27M
Gilead Sciences GILD:US $ 63080M 4872M
Glaxosmithkline GSK:US $ 89689M 10586M
Idera Pharmaceuticals IDRA:US $ 30.13M 4.73M
Merk MRK:US $ 106668M 974M
Minerva Neurosciences NERV:US $ 70.62M 6.5M
Nektar Therapeutics NKTR:US $ 1024.12M 93.07M
Novartis NOVN:VX SF 125218M 6577M
Regeneron Pharmaceuticals REGN:US $ 26348.7M 913.9M
Sarepta Therapeutics SRPT:US $ 3056.15M 91.82M
Tg Therapeutics TGTX:US $ 303.03M 76.6M
Vertex Pharmaceuticals VRTX:US $ 14256.1M 823.6M